News Channels

06 Apr 2020 Initiation of two-centre compassionate use study involving namilumab in the treatment of individual patients with rapidly worsening COVID-19 infection in Italy
06 Apr 2020 Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium
06 Apr 2020 FDA clears investigational new drug application for mesoblast to use remestemcel-L in patients with acute respiratory distress syndrome caused by COVID-19
04 Apr 2020 ORYZON Presents Efficacy Data From its Two Vafidemstat Clinical Trials in Alzheimer’s Disease at the Virtual AAT-AD/PD 2020 Conference
04 Apr 2020 I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome (CRS) Associated with Severe Coronavirus Disease 19 (COVID-19)
04 Apr 2020 XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered Patients
04 Apr 2020 Gracell Announces China NMPA Acceptance of Investigational New Drug Application for GC007g Cell Therapy for CD19 Positive Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
04 Apr 2020 Axon Presented Positive Phase II Trial Results of AADvac1 at AAT-AD/PD 2020
04 Apr 2020 UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
04 Apr 2020 Nucala (mepolizumab) is the first anti-IL5 biologic to report positive phase 3 results in patients with nasal polyps
04 Apr 2020 Update on GSK actions to support the global response to COVID-19
04 Apr 2020 Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline
04 Apr 2020 panCELLa Extends Exclusive License to Astellas
04 Apr 2020 Dupixent® (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years
04 Apr 2020 Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 diabetes in the EU
04 Apr 2020 U.S. Food and Drug Administration (FDA) Approves Reblozyl® (luspatercept-aamt) , the First and Only Erythroid Maturation Agent, to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
03 Apr 2020 Biotest is developing with Trimodulin a COVID-19 therapy for patients with a severe course of the disease
03 Apr 2020 Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies
03 Apr 2020 Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19
03 Apr 2020 Henlius Novel Anti-EGFR Monoclonal Antibody Demonstrated Favorable Safety and Tolerability Profile in Its Phase 1 Clinical Study

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up